Grifols

What Grifols does

Grifols is a Barcelona-headquartered global healthcare company founded in 1909 that develops, manufactures, and markets plasma-derived medicines, diagnostic solutions, and hospital pharmacy products. Its core technology platform is plasma fractionation and purification, producing immunoglobulins (Gamunex-C, Xembify, Flebogamma DIF, YIMMUGO), albumin (Albutein, Plasbumin), coagulation factors (Koate, Fanhdi, Alphanate, AlphaNine), specialty proteins (Prolastin-C for Alpha-1 antitrypsin deficiency, Thrombate III, FESILTY), and the small-molecule Tavalisse for immune thrombocytopenia. The Biopharma division, which represents approximately 85% of group revenue (EUR 6.4 billion of EUR 7.524 billion in FY2025), is supported by a vertically integrated supply chain including nearly 300 captive plasma donation centers in the US plus a Canadian network acquired from Kedrion.

The company operates four segments: Biopharma (plasma-derived medicines), Diagnostic (transfusion medicine instruments and reagents), Bio Supplies (biological reagents), and Healthcare Solutions for Hospitals (IV solutions under the GRI-BAG brand and the GRI-FILL automated compounding system). Revenue is generated primarily through B2B sales to hospitals, healthcare providers, and government health systems in over 110 countries, with pricing negotiated through commercial contracts, hospital supply agreements, and government reimbursement rather than public pricing. Distribution combines direct enterprise sales, pharmaceutical wholesalers, and the company's own plasma donation centers. Key recent strategic actions include the EUR 2 billion Biotest AG acquisition (completed April 2022), the EUR 1 billion senior secured notes refinancing (April 2024), FDA approvals for FESILTY and pediatric Thrombate III (2025), a Google Cloud AI partnership (November 2025), a EUR 160 million Barcelona manufacturing plant groundbreaking (June 2026), and the board's approval to explore a US IPO of the American Biopharma business (March 2026). Headquartered in Sant Cugat del Vallès, Barcelona, Grifols is publicly listed on Spain's IBEX 35 and trades as an ADR on NASDAQ under ticker GRFS, with a market capitalization of approximately EUR 5.5 billion as of June 2026 and a workforce spanning 110+ countries.

Name

Grifols

Legal name

Grifols, S.A.

Website

https://grifols.com

Company type

Public

Founded year

1909

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Grifols is a Barcelona-founded global healthcare company that develops and manufactures plasma-derived medicines, diagnostics, and hospital pharmacy solutions, serving patients with rare and chronic diseases across 110+ countries through a vertically integrated network of nearly 300 US plasma donation centers.

Ownership category

akta.pro rank

Product category

Plasma-derived Biopharmaceuticals

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

akta.pro secondary industries

Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Blood Bank/Transfusion Medicine LIS (HLACAMAE)

Keywords

• Plasma-derived medicines
• Immunoglobulin therapies
• Coagulation factor concentrates
• Transfusion medicine diagnostics
• Hospital pharmacy solutions

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Biopharma (Plasma-derived medicines): Primary revenue driver generating approximately 85% of group revenue (€6.4 billion of €7.524 billion in 2025). Includes plasma collection, fractionation, and manufacturing of immunoglobulins, albumin, coagulation factors, and specialty proteins.
2. Diagnostic Solutions: Provides diagnostic solutions for transfusion medicine, including instruments, reagents, and systems for blood typing, screening, and disease detection.
3. Bio Supplies: Provides biological supplies and reagents to healthcare facilities and laboratories.
4. Healthcare Solutions for Hospitals: Hospital pharmacy solutions including parenteral nutrition, IV solutions, and automated compounding systems.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Grifols is a global plasma-derived biopharmaceutical manufacturer that develops, produces, and markets immunoglobulin therapies, albumin, coagulation factors, alpha-1 antitrypsin, and specialty proteins through vertical integration from its network of nearly 300 plasma donation centers. It also provides diagnostic solutions for transfusion medicine, biological supplies, and hospital pharmacy systems including IV solutions and automated compounding.

Product overview

Grifols is a Barcelona-based global healthcare company specializing in plasma-derived medicines and biopharmaceuticals. The company operates across four main divisions: Biopharma (plasma-derived medicines including immunoglobulins, albumin, coagulation factors, and alpha-1 therapies), Diagnostic (diagnostic solutions), Bio Supplies (biological supplies), and Healthcare Solutions for Hospitals (IV solutions and automated compounding systems like GRI-FILL). The product portfolio includes flagship brands such as Gamunex-C and Xembify (immunoglobulins), FESILTY (fibrinogen concentrate), Prolastin-C (alpha-1 therapy), Albutein and Plasbumin (albumin products), THROMBATE III (antithrombin), Koate and Fanhdi (factor VIII), and Tavalisse (ITP treatment). Grifols also offers hospital pharmacy solutions including GRI-BAG IV solutions and GRI-FILL automated compounding systems. The company operates nearly 300 plasma donation centers in the U.S. and serves patients in over 110 countries.

Differentiator

Problem solved

Functional benefit

Brands

• FESILTY: Fibrinogen concentrate for treating acute bleeding episodes in congenital fibrinogen deficiency
• Xembify
• Gamunex
• Yimmugo
• Thrombate III
• Prolastin
• Albutein
• Koate
• Flebogamma DIF
• Tavalisse

Products and services

• FESILTY (fibrinogen, human-chmt) FDA-approved fibrinogen concentrate for treating acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, offering rapid reconstitution in approximately three minutes and room temperature storage.
• Gamunex-C (Intravenous Immunoglobulin) Intravenous immunoglobulin (IVIG) product used for treating primary immunodeficiency and other immunological conditions.
• Xembify (Subcutaneous Immunoglobulin) Subcutaneous immunoglobulin (SCIG) product for primary immunodeficiency, allowing self-administration at home.
• Flebogamma DIF (Intravenous Immunoglobulin) Intravenous immunoglobulin product for primary immunodeficiency and neurological disorders.
• YIMMUGO Immunoglobulin therapy for primary immunodeficiency (PI), approved by the FDA and launched in the U.S. market in 2026.
• Prolastin / Prolastin-C (Alpha-1 Antitrypsin) Alpha-1 antitrypsin replacement therapy for patients with alpha-1 antitrypsin deficiency (Alpha-1), affecting lungs and liver.
• Albutein (Human Albumin) Human serum albumin solution used for plasma volume restoration and maintenance of colloidal pressure.
• Plasbumin (Human Albumin) Human serum albumin product for clinical use in hypovolemia and hypoalbuminemia.
• THROMBATE III (Antithrombin III) Antithrombin concentrate for treating hereditary antithrombin deficiency, approved for pediatric use in addition to adult indications.
• Koate (Antihemophilic Factor VIII) Coagulation factor VIII concentrate for treating hemophilia A.
• Fanhdi (Antihemophilic Factor VIII) Antihemophilic factor (factor VIII) concentrate for hemophilia A treatment.
• Alphanate (von Willebrand Factor/Factor VIII) Combined von Willebrand factor and coagulation factor VIII product for treating von Willebrand disease.
• AlphaNine (Coagulation Factor IX) Coagulation factor IX concentrate for treating hemophilia B.
• Tavalisse/Tavlesse (Fostamatinib) Spleen tyrosine kinase (SYK) inhibitor oral tablet for treating thrombocytopenia in adults with chronic immune thrombocytopenia (ITP).
• Vistaseal (Fibrin Sealant) Topical fibrin sealant for hemostatic use during surgical procedures.
• GRI-BAG (IV Solutions) Intravenous solutions product line including normal saline, dextrose solutions, and Ringer's solutions in flexible bags.
• GRI-FILL (Automated Compounding) Automated compounding system for preparing IV admixtures in hospital pharmacies, improving accuracy and reducing medication errors.
• DIETGRIF (Nutritional Supplements) Line of nutritional supplements including protein drinks, puddings, and specialized formulas for patients needing nutritional support.

Quantifiable outcome

• €7.524 billion in full-year 2025 revenue with 7% year-over-year growth
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Alpha-1 Foundation / AlphaDetectcoreStrategic or Co-development Partner · 5 June 2026Grifols became the inaugural industry sponsor of AlphaDetect, a nonprofit detection organization powered by the Alpha-1 Foundation, to accelerate detection of Alpha-1 Antitrypsin Deficiency. Grifols has screened over 1.5 million people through its existing testing program, with over 90% of affected individuals still undetected. AlphaDetect will provide free genetic testing in Durham, North Carolina laboratory and expand detection strategies and provider education programs.
• National Institute for Bioprocessing Research and Training (NIBRT)minorStrategic or Co-development Partner · 11 March 2026NIBRT developed tailored workforce training programs in partnership with Grifols and Bristol Myers Squibb to address global shortage of experienced biopharmaceutical manufacturing engineers.
• Google CloudcoreTechnology or Integration · 5 November 2025Grifols partnered with Google Cloud on biopharmaceutical development as part of broader AI integration in drug discovery and manufacturing processes.
• KedrionminorChannel Partner/ Reseller/ Distributor · 4 January 2022Grifols acquired its first plasma donation center in Canada from Kedrion for USD 4 million, expanding its operations in Canada as part of its strategy to enhance plasma medicines supply and increase self-sufficiency.
• Tiancheng International Investment Ltd.coreStrategic or Co-development Partner · 17 September 2021Grifols acquired a majority stake in Biotest through purchase of Tiancheng International Investment Ltd.'s shares and a voluntary tender offer to remaining shareholders for approximately EUR 2 billion.

Scale indicators16 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Octapharma: Octapharma is one of the largest privately-held plasma fractionators globally, competing directly with Grifols in immunoglobulins (Octagam), coagulation factors, and albumin. Its privately-held status and global fractionation footprint make it a close operational and product-portfolio comparable.
• CSL Limited (CSL Behring): CSL Behring is the global market leader in plasma-derived therapeutics, producing immunoglobulins, albumin, and coagulation factors. It is the most directly comparable competitor to Grifols across the same product categories, customer base (hospitals and government health systems), and vertical integration model.
• Kedrion Biopharma: Kedrion is an Italy-based plasma products company producing immunoglobulins, albumin, and coagulation factors. Grifols has transacted with Kedrion (acquiring its Canadian plasma center for USD 4M in 2022), making it a direct peer in both plasma collection and finished plasma-derived therapies.
• Bio Products Laboratory (BPL): BPL is a UK-based plasma fractionator producing immunoglobulins, albumin, and coagulation factors. It is a direct competitor in plasma-derived therapies and shares Grifols' vertical integration model from plasma collection through finished therapeutic products.
• Baxalta (Shire) — now Takeda: Pre-acquisition Baxalta was a standalone leader in plasma-derived therapies (Gammagard, Hemofil, Advate). Now part of Takeda, it remains the most directly comparable historical peer in the immunoglobulin and hemophilia franchises where Grifols competes with Xembify, Gamunex, and Koate.
• Takeda Pharmaceutical: Takeda's Plasma-Derived Therapies unit, built on the Shire/Baxalta acquisition, is a major global competitor in immunoglobulins (Gammagard), albumin, and coagulation factors. It competes head-to-head with Grifols in immunoglobulin and rare disease franchises across the same hospital and specialty channels.

Broad incumbents

• Bio-Rad Laboratories: Bio-Rad is a diagnostics and life science research company with a significant presence in blood typing, screening reagents, and quality controls for transfusion medicine. It competes with Grifols Diagnostic in serving blood banks and transfusion medicine laboratories.
• Hologic: Hologic is a major diagnostics company that previously sold its NAT donor screening unit to Grifols in 2017. It overlaps with Grifols' Diagnostic Solutions division in transfusion medicine and blood screening instruments and reagents, serving similar hospital and blood bank customers.
• Sanofi: Sanofi is a broad pharmaceutical incumbent with exposure to plasma-derived and rare disease therapies (notably through its historic Genzyme franchise and broader immunology portfolio). While not a pure-play plasma company, it overlaps with Grifols in immunoglobulin-adjacent indications and competes for hospital and specialty channel share.

Emerging players

• LFB Group: LFB is a French state-linked plasma fractionator producing immunoglobulins, coagulation factors, and albumin. It is a smaller but growing plasma products competitor with direct overlap in product portfolio and European hospital customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/grifols_press
• LinkedInlinkedin.com/company/grifols

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries4 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A10 records

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grifols